Unternehmen wird geladen
Just reported
Q3 FY2026 results
From Citius Oncology's results release of 26. Oktober 2026; its quarterly report has since been filed.
Revenue
Actual
1,5M $
-10 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
-0,08 $
Guided
—
No guide given
Operating income, GAAP
Actual
-8,7M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Citius Oncology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B $A
NBIXNeurocrine Biosciences, Inc.16,9B $A+
ELANElanco Animal Health Incorporated13,4B $A
KNSAKiniksa Pharmaceuticals International, plc8,2B $A+
LQDALiquidia Corporation5,2B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Gebaut aus den eigenen Einreichungen von Citius Oncology, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
